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ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
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It was established by the 1980’s that drug treatment of
elevated blood pressure (BP) reduces the risks of
cardiovascular complications of hypertension. The prevailing
assumption among clinicians and regulators was, and
probably continues to be, that the benefits of antihypertensive
treatment were a direct consequence of the reduction in
systolic and/or diastolic BP. Based on this premise, we have
seen a flood of new antihypertensive agents from multiple
classes of drugs introduced into the marketplace. The
scientific documentation has often consisted of small, short-
term trials. As long as the new agents are superior to placebo
in reducing BP, and as long as they are reasonably free of
side effects, the drugs receive regulatory approval. Clinicians
now have more than 100 antihypertensive drugs from which
to choose. Because the blood-pressure-lowering potential of
these drugs is fairly similar, use of individual pharmaceutical
agents is determined more by marketing forces than by
science. A health services concern is that there is a greater
than 20-fold difference in drug cost [1].
The key question today is, “Does it matter how elevated BP is
lowered?” This question is best answered by randomized
clinical trials that compare antihypertensive agents. However,
a number of issues and concerns have been raised about the
design of these trials. Regulatory agencies prefer placebo-
controlled trials, since they want to know whether a drug is
effective for its intended use and whether it is reasonably safe.
Comparative or active-controlled trials have other objectives
and provide answers along the superiority–inferiority axis.
Although extremely relevant clinically, the regulatory agencies
have limited interest and use for information regarding which
drug is superior. It is currently not a regulatory issue.
Comparative trials are a cause for concern to the
pharmaceutical industry, since such trials may produce losers
(inferior drugs), whereas the outcome of placebo-controlled
trials of new antihypertensive agents is, for the industry, less
risky. To lessen the risks that a drug may be inferior to that of
a competitor, there is an unfortunate tendency to compare the
new agent to the least effective standard therapy, sometimes
in an inadequate dose. Another approach is to proceed with
only a small sample size, which is inadequate to detect reliably
meaningful differences among drugs. Thus, a drawback of
comparative trials is the large-scale required.
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Abstract
The key question in hypertension research today is, “Does it matter how elevated blood pressure is
lowered?” The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
initiated in 1994 serves as a model for comparative trials. Its strengths include its independent
sponsorship, scope and design. The alpha-blocker arm was stopped early; doxazosin was shown to be
clearly inferior to low-dose chlorthalidone not only in preventing heart failure, but also stroke, in spite of
similar blood pressure reduction. The findings have major public health implications as pointed out by
Krakoff in this journal. Other commentaries by Gavras and Gavras and Hooper discuss possible
mechanisms behind the excess of cardiovascular events in doxazosin-treated patients.
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The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT), initiated in 1994, was
one of the first major comparative trials with clinical
outcomes [2]. Its strengths include: independent
sponsorship (the National Heart, Lung, and Blood Institute);
its scope (comparison of 4 drugs from different drug
classes); optimal selection of standard/control treatment
(low-dose diuretics); a double blind design; its sample size
(40,000 high-risk hypertensives to be treated for 4–8 years);
and the selection of trial outcomes (all major vascular
complications of hypertension).
ALLHAT addresses the question of whether representatives
of the newer and more expensive antihypertensive agents:
lisinopril (angiotensin-converting enzyme inhibitor), doxazosin
(alpha-blocker), and amlodipine (calcium-channel blocker),
are more effective as first-line drugs than a generic agent,
chlorthalidone (low-dose diuretic), in reducing the risk of
cardiovascular disease. A total of 42,448 patients were
randomized to ALLHAT by January, 1998.
The doxazosin arm was terminated two years early for two
reasons [3]. First, there was a highly significant (25%) excess
risk of major cardiovascular events (a prespecified secondary
endpoint) in the doxazosin group in comparison to the
chlorthalidone group. Second, the likelihood of doxazosin
emerging as superior to low-dose chlorthalidone was very
remote. This excess of cardiovascular events with doxazosin
was driven by a doubling in the risk of congestive heart failure,
both primarily hospitalized and fatal cases. The annual heart
failure rate was 2% in the doxazosin group but 1% in the
chlorthalidone group. In addition, there was a 20% excess in
the relative risk of stroke, and 15% excesses in coronary
revascularizations and angina, in the doxazosin group.
However, the risks of major coronary events (the prespecified
primary endpoint) and all-cause mortality were not different
between the two treatment groups. The fact that the achieved
blood pressures were similar throughout the duration of the
trial indicates that non-blood-pressure-related mechanisms
are involved, which could explain these differences.
Many commentaries have been written about the doxazosin
findings. The more persuasive ones conclude that alpha-
blockers should no longer be considered first-line agents for
hypertension in high-risk, elderly adults [4–6]. Others raise
questions of a technical nature, but fail to realize the public
health implication of the ALLHAT findings [7–9]. Among the
approximately one million users of doxazosin in the United
States and Europe, one could expect as many as 10,000
unnecessary cases of advanced heart failure every year [6].
This issue of Current Controlled Trials in Cardiovascular
Medicine features three commentaries on ALLHAT. Krakoff
[10] raises a critical question, “Should the results of ALLHAT
be considered as revealing drug toxicity or of the lesser charge
of ineffectiveness?” He suggests that doxazosin, “may be
ineffective and perhaps little better than placebo, for the many
patients at higher risk for heart failure”. Regardless of the
answer, actions should be taken to inform treating clinicians.
To date, the manufacturer of doxazosin, Pfizer, has refused to
issue even a “Dear Doctor” letter with a proper warning.
The other two commentaries by Gavras and Gavras [11] and
Hooper [12] discuss potential mechanisms behind the
observed excess of cardiovascular events. Gavras and
Gavras speculate that alpha-adrenergic blockage would lead
to small elevations of arginine vasopressin. This systemic
pressor hormone could become important through its
pressor action in elderly patients and in those with diabetes,
triggering congestive heart failure and myocardial ischemia.
Hooper discusses the potential role of heat shock proteins in
explaining the ALLHAT findings. These proteins have vital
functions in the body, protecting cells from injury through
multiple mechanisms. Alpha-adrenergic stimulation with
norepinephrine increases the levels of heat shock proteins,
while alpha-adrenergic blockade decreases it. A drug-
induced decrease could lead to increased vulnerability of the
cardiovascular system to injury.
Mechanisms of action are always difficult to prove. We may
never know with certainty why doxazosin had unfavorable
cardiovascular effects in ALLHAT. However, we stand on a
solid scientific foundation when we conclude that doxazosin
is an inferior antihypertensive agent and it should only be
used if first-line agents – low-dose diuretics, beta-blockers,
and angiotensin-converting enzyme inhibitors – fail to achieve
blood pressure control or cannot be tolerated.
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